Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis : Episode 8
Guidance on Transitioning from TNFi to Non-TNF Targeted Therapies
Experts discuss American College of Rheumatology guidelines on transitioning patients from TNF inhibitors to non-TNF targeted therapies like Janus kinase inhibitors, as well as factors influencing treatment switching decisions in clinical practice.
EP: 1.Intro and Welcomes
EP: 2.Evolving Goals in Rheumatoid Arthritis Treatment: Defining and Achieving Clinical Remission
EP: 3.Prevalence and Management of Poorly Controlled Rheumatoid Arthritis in Clinical Practice
EP: 4.Complications and Prognostic Factors in Uncontrolled Rheumatoid Arthritis
EP: 5.Evaluating and Adjusting Rheumatoid Arthritis Treatment: Adhering to ACR Guidelines for csDMARDs and Advanced Therapies
EP: 6.Exploring the Discrepancy Between Patient Perception and Disease Activity Assessments
EP: 7.Achieving Low Disease Activity and Remission: Managing Patient Expectations
Now Viewing
EP: 8.Guidance on Transitioning from TNFi to Non-TNF Targeted Therapies
EP: 9.Advanced Treatment Options for RA: Exploring the Data
EP: 10.Guiding Treatment Decisions: The Role of Remission Data and Head-to-Head Comparisons
EP: 11.JAK Inhibitors vs TNF Inhibitors: Effects on Administration, Efficacy, and Safety
EP: 12.JAK Inhibitor Selectivity and Dose-Related Toxicity
Video content above is prompted by the following:
- For patients receiving tumor necrosis factor (TNF) inhibitors, please describe American College of Rheumatology guidance on switching to a non-TNF targeted therapy, such as Janus kinase inhibitors, vs cycling.
- In your own practice, what factors would make you consider switching?
Recent Videos
Related Content
